HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
- PMID: 28799059
- DOI: 10.1007/s10549-017-4453-8
HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
Abstract
Purpose: Anti-HER2 neoadjuvant chemotherapy has been widely used in HER2-positive breast cancer patients; however, pathologic complete response (pCR) is achieved in only 40-50% of patients. The aim of this study was to investigate the association of HER2 intratumoral heterogeneity (ITH) with response to anti-HER2 neoadjuvant chemotherapy.
Methods: Assessment of HER2 ITH was performed on whole tissue sections of pre-treatment samples from a cohort of 64 invasive breast carcinoma cases originally considered positive for HER2 and treated with anti-HER2 neoadjuvant chemotherapy. Both HER2 gene signal and protein expression were simultaneously evaluated by means of a single-slide dual assay, designated as a HER2 gene-protein assay (GPA). HER2 GPA was carried out as well on surgical resection tissues from 25 cases with incomplete therapeutic response.
Results: Nineteen of 64 cases (30%) showed HER2 ITH. Significantly more cases with HER2 ITH were found in the incomplete response group (56%, 14/25) than in the pCR group (13%, 5/39). Patients without ITH detectable by GPA had a 76% pCR outcome (34/45), as compared to 26% (5/19) for those with detectable ITH. Multivariate analysis demonstrated HER2 ITH, progesterone receptor positivity, and relatively low HER2/chromosome 17 centromere ratio to be significantly associated with incomplete response.
Conclusions: HER2 ITH analyses conducted with GPA method revealed that HER2 ITH is an independent factor predicting incomplete response to anti-HER2 neoadjuvant chemotherapy.
Keywords: Anti-HER2 neoadjuvant chemotherapy; Breast carcinoma; Directed therapy response predictor; HER2 gene-protein assay; HER2 intratumoral heterogeneity.
Similar articles
-
Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.Virchows Arch. 2021 Jul;479(1):13-21. doi: 10.1007/s00428-021-03036-2. Epub 2021 Jan 26. Virchows Arch. 2021. PMID: 33496805
-
Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.Clin Breast Cancer. 2018 Apr;18(2):e237-e244. doi: 10.1016/j.clbc.2017.11.001. Epub 2017 Nov 9. Clin Breast Cancer. 2018. PMID: 29198959 Free PMC article.
-
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.Clin Breast Cancer. 2015 Feb;15(1):24-30. doi: 10.1016/j.clbc.2014.07.010. Epub 2014 Aug 15. Clin Breast Cancer. 2015. PMID: 25205424
-
The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer.Cancer Treat Rev. 2018 Jan;62:9-17. doi: 10.1016/j.ctrv.2017.10.009. Epub 2017 Oct 31. Cancer Treat Rev. 2018. PMID: 29127857 Review.
-
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Cancer Treat Rev. 2017. PMID: 28525810 Review.
Cited by
-
Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR.iScience. 2024 Apr 15;27(5):109750. doi: 10.1016/j.isci.2024.109750. eCollection 2024 May 17. iScience. 2024. PMID: 38711454 Free PMC article.
-
Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.World J Surg Oncol. 2024 Apr 6;22(1):88. doi: 10.1186/s12957-024-03365-x. World J Surg Oncol. 2024. PMID: 38582875 Free PMC article.
-
High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer.Cancers (Basel). 2024 Mar 5;16(5):1062. doi: 10.3390/cancers16051062. Cancers (Basel). 2024. PMID: 38473420 Free PMC article.
-
Machine learning-based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results.Cancer Med. 2024 Feb;13(3):e6946. doi: 10.1002/cam4.6946. Epub 2024 Jan 17. Cancer Med. 2024. PMID: 38234171 Free PMC article.
-
TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2+ breast cancer.Arch Toxicol. 2024 Mar;98(3):865-881. doi: 10.1007/s00204-023-03670-6. Epub 2024 Jan 11. Arch Toxicol. 2024. PMID: 38212449
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous